Hengan International Group (1044) H2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2025 earnings summary
17 Mar, 2026Executive summary
Revenue grew 1.8% year-over-year to RMB23.07bn, with net profit up 10.3% to RMB2.54bn and core business segments rising 1.9%.
Gross profit margin improved to 33.8%, operating profit rose 3.9% to RMB3.48bn, and EPS increased to RMB2.227.
Maintained a leading market position in tissue products, stable dividend payments, and strong net cash position.
E-commerce and new retail channels grew 10.1%, now 36.9% of total sales.
Final dividend of RMB0.70 per share proposed, with full-year payout at RMB1.40.
Financial highlights
Core revenue (tissue and hygiene products) reached RMB20.7bn, up 1.9% from 2024.
Gross profit increased 6.6% to RMB7.81bn; gross margin at 33.8%.
Net profit attributable to shareholders: RMB2.54bn (up 10.3%); basic and diluted EPS: RMB2.227 (up 10.5%).
Net cash position improved to RMB6.9bn; cash and bank balances plus long-term deposits: RMB22.63bn.
Gearing ratio increased to 72.3% from 62.6% year-over-year.
Outlook and guidance
Revenue is expected to remain stable in 2026, driven by premium product growth and omni-channel sales.
Focus on premiumisation, omni-channel expansion, and prudent promotional spending.
Plans to expand production capacity, upgrade technology, and accelerate digital transformation.
Anticipates stable gross profit margin despite rising wood pulp prices.
Latest events from Hengan International Group
- Revenue and profit fell, but e-commerce and new retail sales rose and dividend was stable.1044
H2 20244 Dec 2025 - Tissue paper growth and e-commerce expansion offset margin pressure from hygiene segment.1044
H1 20254 Dec 2025 - Net profit rose 15% to RMB1.41 bn on higher margins and premium product sales.1044
H1 20244 Dec 2025